A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million people estimated to be living with the disease worldwide. As MS is an ...

For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system that causes disruptions in the flow of information within the brain and between the brain and body, eventually causing ...

A sponge-like implant in mice helped guide a treatment that slowed or stopped a degenerative condition similar to multiple sclerosis in humans. It also gave University of Michigan researchers a first ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. March is Multiple Sclerosis Awareness Month, a time to ...

In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in significant improvements in fatigue. Researchers say ...

Multiple sclerosis (MS) and muscular dystrophy (MD) have distinct differences. MS affects the protective covering around nerve fibers, while MD affects the muscle fibers. The causes of MS and MD are ...

A Leap Forward in MS Research For years, scientists have puzzled over what causes multiple sclerosis (MS), a neurological ...

Sponsored by Novartis Jamie Lynn Sigler opens up about self-advocacy, finding her treatment plan and why your voice should be ...

When Shanel Gamboa's legs started to tingle and go numb last fall, she attributed it to working long shifts as a neuroscience nurse with Lehigh Valley Health Network. But one morning in October, ...

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low ...